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AbstrAct
The recent emergence and re-emergence of viral 
infections transmitted by vectors—Zika, chikungunya, 
dengue, Japanese encephalitis, West Nile, yellow fever 
and others—is a cause for international concern. Using as 
examples Zika, chikungunya and dengue, we summarise 
current knowledge on characteristics of the viruses and 
their transmission, clinical features, laboratory diagnosis, 
burden, history, possible causes of the spread and 
the expectation for future epidemics. Arboviruses are 
transmitted by mosquitoes, are of difficult diagnosis, can 
have surprising clinical complications and cause severe 
burden. The current situation is complex, because there 
is no vaccine for Zika and chikungunya and no specific 
treatment for the three arboviruses. Vector control is 
the only comprehensive solution available now and this 
remains a challenge because up to now this has not been 
very effective. Until we develop new technologies of control 
mosquito populations, the globalised and urbanised world 
we live in will remain vulnerable to the threat of successive 
arbovirus epidemics.
IntroductIon
The emergence and re-emergence of viral 
diseases transmitted by vectors, given the 
capacity of vectors to transmit a number of 
viral infectious agents, raises global concerns 
about the causes of the emergence, threats to 
health, burden and the feasibility of preven-
tion and control. There are many vector-borne 
viral diseases: West Nile fever, dengue, tick-
borne, yellow fever, chikungunya, Rift Valley 
fever, Zika and Japanese encephalitis, among 
others. Zika virus (ZIKV), chikungunya virus 
(CHIKV) and dengue virus (DENV) have 
similar epidemiology, transmission cycles in 
urban environments and clinical symptoms 
at onset (although complications vary mark-
edly). They attracted interest in recent years 
due to their increasing incidence, expanding 
geographical range, possible effects caused 
by cocirculation and the unpredictable 
health threats and burden. An indication 
of this concern was WHO declaring the 
increase in microcephaly and Guillain-Barré 
syndrome (GBS), now known to be caused by 
ZIKV infection, a Public Health Emergency of 
International Concern.
In this review, we address (using as exam-
ples Zika, chikungunya and dengue): (1) 
the diseases—virus, transmission, clinical 
symptoms and diagnosis; (2) the history; (3) 
the possible causes of the recent outbreaks; 
and (4) the burden and the threats. 
the viruses
More than 50% of the viruses in the genus 
Flavivirus, family Flaviviridae, cause disease in 
humans, including dengue, yellow fever, West 
Nile and Zika viruses.1 Flavivirus virions are 
small in size of 40–50 nm, spherical with lipid 
envelopes, which contain a single-stranded, 
non-segmented RNA. The genome of flavivi-
ruses is approximately 11 000 bases long and 
they share common group epitopes on the 
envelope protein that can cross-react in sero-
logical tests.2
Our knowledge of ZIKV is limited. The 
molecular information reveals that it origi-
nated in East Africa and subsequently spread 
to West Africa, Asia and the Americas in three 
main clusters, two African clusters (the Nige-
rian cluster and the MR766 cluster) and the 
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Key questions
What is already known about this topic?
 ► The emergence and re-emergence of mosquito-
borne disease has attracted interest in recent years 
due to their increasing incidence and geographical 
expansion. 
What are the new findings?
 ► The cocirculation of three arboviruses transmitted 
by the same mosquito is a reality in many places; 
however, the burden to the population’s health is 
still not known.
recommendations for policy
 ► The situation is worrying; there is an urgent need 
for development of vaccines, better diagnostic tests 
and vector control tools.
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Asian strain, which is the one found in the Americas, 
Pacific Islands and Cape Verde epidemics.3 It is not yet 
known whether the genetic variations have implication 
for transmissibility or clinical manifestations, nor if a 
previous flavivirus infection increases severity, although 
mutations in flavivirus genome are known to impact viru-
lence and immunogenicity.4
Chikungunya is a member of the genus Alphavirus and 
family Togaviridae; it has a capsid, a phospholipid enve-
lope and a single-stranded RNA genome. The Alphavirus 
group contains 28 known viruses including o’nyong-
nyong, Ross River and Mayaro.5 There are four CHIKV 
genotypes: the East-Central-South Africa, West Africa, 
Asian and Indian Ocean lineage.6
There are four genetically distinct serotypes of DENV 
(DENV-1, DENV-2, DENV-3 and DENV-4), and multiple 
lineages of each serotype, which are often geographically 
based.7 DENV infections with one serotype provide long 
immunity against that particular serotype; cross immu-
nity to the others is temporary and may lead to increased 
severity.1
trAnsmIssIon
The most common mode of transmission of Zika, chikun-
gunya and dengue is by their common vector, Aedes. The 
mosquito is infected during a viraemic blood meal and 
after the extrinsic incubation period, the virus is present 
in the mosquito salivary gland and can be transmitted to 
humans by a mosquito bite. Several factors can influence 
the dynamics of transmission, such as environmental and 
climate factors, the interaction between host and path-
ogen, and the development of immunity in the popula-
tion.8
Aedes aegypti and A. albopictus are the main vectors of 
Zika, chikungunya and dengue, but a larger range of Aedes 
species are likely vectors in Africa and Asia.9–11 A. aegypti 
is one of the most capable vectors: it feeds primarily on 
humans, frequently bites several times in a single meal, 
has an almost imperceptible bite and lives very close to 
humans11; however, it is geographically restricted because 
it does not winter well in cold climates. A. albopictus has 
a wider geographical distribution (it can be found in 
subtropical and temperate climates), it is resilient and 
aggressive, can survive in rural as well as urban environ-
ments, is relatively long lived (4–9 weeks) and is more 
able to survive through cold winters.12 Both A. aegypti and 
A. albopictus bite primarily during the day, limiting the 
usefulness of insecticide-impregnated bednets. Overall, 
the ability of a vector species to transmit a pathogen 
depends on the location and time. It is notably difficult 
to avoid mosquito bites and to control mosquito popula-
tions, especially in tropical climates.13
Non-vector transmission of arbovirus has been reported 
by vertical transmission,14–16 sexual transmission,17 18 by 
transfusion18 19 and in nosocomial settings.20 It is not 
known what role these routes of transmission play during 
the current Zika epidemics: vector transmission is likely 
to be required for fast epidemic spread—epidemics of 
sexually transmitted diseases tend to be characterised 
by slower progress and require long infectious periods. 
Vertical transmission of ZIKV from pregnant women 
to the fetus is responsible for the epidemic of micro-
cephaly.21 Reservoirs were part of the initial cycle in 
Africa, but no animal reservoir has been identified, so 
far, outside Africa.
clinical symptoms
Asymptomatic and mild clinical forms of Zika, chikun-
gunya and dengue may account for a large proportion 
of all infections. When present, initial symptoms can be 
similar, and clinically non-specific, including fever, head-
ache, myalgia, arthralgia, maculopapular rash, retro-or-
bital pain and lymphadenopathies.22 In the early phase, 
it can be difficult to distinguish between these three 
diseases, so clinical diagnosis is challenging. Algorithms 
comparing clinical manifestation of Zika, chikungunya 
and dengue have been proposed22; however, their sensi-
tivity and specificity have not been estimated.
Little is known so far of the natural history of Zika 
infection, and the initial perception as a mild disease has 
been challenged by the continued discovery of severe 
neurological complications, including but not restricted 
to congenital Zika infection and GBS. Preliminary esti-
mates of the incubation period were done based on 
recipients of blood transfusions in French Polynesia who 
tested positive to Zika by RT-PCR and who reported clin-
ical symptoms of the disease from 3 to 10 days after the 
transfusion.18 A more recent study, with 197 symptom-
atic travellers with recent Zika, indicated an estimated 
incubation period of 3–14 days.23 Common symptoms of 
uncomplicated Zika are short term and include low-grade 
fever descending rash, myalgia, conjunctivitis, headache, 
oedema and vomiting.9
The incubation period of chikungunya ranges from 1 
to 12 days. Clinical onset is usually abrupt with high fever, 
headache, myalgia and moderate or severe arthralgia that 
affects especially extremities.5 The joint pain associated 
with chikungunya can be very severe; duration can vary 
from few days to years, resulting in an acute, subacute or 
chronic disease. Estimating the disability burden caused 
by chikungunya complications is a research priority.
The incubation period of dengue ranges from 3 to 
14 days. Most cases are self-limiting: typically, patients 
develop high fever, sudden-onset skin rash, myalgia and 
headache, and in some cases mild haemorrhagic mani-
festations. There are no differences, in the early phases, 
between cases that will and will not progress to severe 
dengue, characterised by rapid onset of capillary leakage 
with or without haemorrhage accompanied by thrombo-
cytopenia and liver injury and, in some cases, death.1
diagnosis
The challenge in differential clinical diagnosis between 
these three diseases highlights the importance of labo-
ratory diagnostic tests. RT-PCR in serum is the main test 
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for detection of viral nucleic acid of Zika, chikungunya 
and dengue during the initial viraemic phase. The detec-
tion of Zika RNA in serum is limited to the first 5 days of 
the disease.24 Urine may be the specimen of choice to 
enlarge the window of detection of DENV and ZIKV after 
viraemia has faded: PCR positivity is possible for a longer 
window and higher viral loads facilitate virus typing.25 26 
In dengue, ELISA can detect NS1 antigen in the acute 
phase, but this test was not yet available for Zika at time 
of writing.27 Because viraemia is short lived, a negative 
RT-PCR does not rule out Zika infection and serologic 
tests should be performed.
Typically, IgM antibodies last for 2–12 weeks. In patients 
with clinical symptoms, the serum should be collected 4 
days after disease onset and tested for Zika, chikungunya 
and dengue.24 The applicability of IgM might depend on 
the clinical situation; the duration of anti-Zika IgM has 
not yet been established and there are initial indications 
that anti-Zika IgM might be useful in diagnosing congen-
ital Zika syndrome.28 The sensitivity and specificity of IgM 
and IgG tests are poorly established and there is strong 
cross-reactivity between ZIKV, DENV and other flavivi-
ruses. There are research groups working to develop new 
diagnostic approach to consistently differentiate Zika 
infection from other flavivirus; although we have had 
advances, there is still no ideal diagnostic test capable to 
be used in a large scale.29
Plaque reduction neutralisation tests (PRNT) can 
measure virus-specific neutralising antibodies and may 
be able to determine the cause of the primary infection 
with high specificity and clarify cross-reacting results; 
however, PRNT is expensive and very labour intensive.24
History of the three diseases
Dengue has a long history of human interaction. During 
the 19th century, it was recognised as a sporadic disease 
causing occasional epidemics. Records describe a 
dengue-like illness in China as early as the third century 
and are consistent with a dengue epidemic in 1779–1788, 
coinciding with the increase in global naval commerce.7 
A second series of dengue-like pandemic lasted from 
1823 to 1916 moving from Africa to India, to Oceania 
and to the Americas. A new pattern to DENV began 
with the World War II, which brought ecological, demo-
graphic and epidemiological changes which allowed the 
vector to reach high densities and facilitated dispersal of 
DENV serotypes among diverse geographical regions. In 
1950, only nine countries reported cases of dengue; the 
average annual number of cases reported to WHO varied 
from 908 in 1950–1959 to 514 139 in 1990–1999.30
The discovery of Zika and other arboviruses resulted 
from programmes of research on yellow fever sponsored 
by Rockefeller Foundation from 1914 to 1970.27 ZIKV 
was isolated for the first time in 1947 from the blood of 
a sentinel rhesus monkey (Macaca mulatta) in the Zika 
Forest, Uganda.31 The first evidence of human infection 
was the presence of neutralising antibodies in human sera 
collected from East Africa in 1952.32 Since then, sporadic 
cases and serological evidence of Zika were found in 
Africa and Asia; the first large outbreak occurred in Yap 
in 2007.9
CHIKV was first isolated from the blood of a febrile 
individual during an outbreak in Tanzania in 1952.33 
According to Halstead, this virus has escaped from a 
complex African zoonotic cycle into an urban cycle at 
40–50 year intervals since 1823 causing large epidemics 
worldwide.34 Human infections have been documented 
in Thailand, where the virus was first introduced in the 
Asia region; in 1958, over 50 000 cases were recorded35 36; 
Calcutta had an intense circulation of chikungunya in 
1963 and Chennai in 1965. During this period, the disease 
directly affected thousands of people, especially children 
and the elderly. After 1973, there were CHIKV circu-
lation reports until the mid-2000s, when the disease 
re-emerged.36
WHAt Are tHe cAuses of tHe recent spreAd?
Ecological and human factors appear to play a role in 
determining the increased incidence of vector-borne 
diseases; increasing availability of tests and better aware-
ness of clinicians contribute to more frequent recogni-
tion.37 Climate change, urbanisation (in particular with 
degraded urban environments), human behaviours, 
mass gathering events, migration of humans and animals, 
development of air transport and extensive agriculture 
have all been suggested to have contributed to the rapid 
worldwide spread of vector-borne diseases.38
The 2014 Climate Change Report lists points to mecha-
nisms by which climate change can facilitate the spread of 
vector-borne infections: by directly affecting the biology 
of the vectors, their abundance and geographical distri-
bution, including territorial expansion to new areas, and 
changes in the extrinsic incubation period of the patho-
gens. Environmental changes such as flood protection, 
increased urban green spaces, designed to mitigate the 
effects of climate change, can increase the risk of vector-
borne diseases.12 The impact of man on the environment, 
modifying the ecosystems with modern infrastructures, 
irrigation and massive solid waste production, also facil-
itates the development of vectors. Finally, urbanisation 
in poor settings with lack of consistent water supply and 
garbage collection can facilitate mosquito breeding.
The main trigger of the recent pathogen introduction 
is suggested to be the increasing trade and travel, as the 
invasive mosquito can be imported through global trade in 
used tyres, ornamental plants and moving with vehicles.38 
The recent development in air travel enables pathogens 
to reach other continents within the few days in which 
a host is infectious, and even during the latent period 
for some diseases. Travellers could be infected in one 
country and introduce the virus in the other; imported 
cases might result in local transmission and spread the 
virus in areas that have the appropriate mosquito vectors 
establishing local transmission. A key consequence of 
having a well-established vector population and a suitable 
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environment is that a recently introduced pathogen can 
cause an explosive epidemic due to the high number 
susceptible in the population.
Finally, the increased number and density of the human 
population, global land use change and the introduction 
of human commensal vectors may act as selective pres-
sure on pathogens to evolve to take advantage of the new 
environments.38
tHe burden And tHe tHreAts AssocIAted WItH tHese 
tHree ArbovIruses
DENV is the most common vector-borne disease world-
wide, with a 30-fold increased incidence in the past 50 
years,39 endemic in more than 100 countries mostly in 
South America and Southeast Asia and still spreading 
to new areas, including Europe, where outbreaks were 
reported in more than 10 countries since 2010.30 The 
annual average number of dengue cases has increased 
dramatically in recent years: an estimated 390 million of 
people infected, 96 million with clinical symptoms every 
year.40 Although the incidence rates differ according to 
location and season, a prospective cohort showed an inci-
dence of virologically confirmed DENV of 4.6 episodes 
per 100 person-years in Asia and 2.9 episodes per 100 
person-years in Latin America, approximately 10% of all 
episodes of febrile disease.41
The risk of severe cases and death from DENV has 
increased, with the associated economic burden. In a 
prospective cohort of school-age children in a rural area 
in Thailand, febrile DENV had longer duration and 
higher costs than non-DENV febrile illness42; even mild 
clinical dengue adds a significant hospitalisation burden 
in some countries (and more than 70% of hospitalised 
cases of dengue do not meet the definition of severe 
dengue).41 The number of DENV-related deaths is large 
worldwide. In 2013, it was estimated that DENV is respon-
sible for 576 900 years of life lost and 1.14 million disabil-
ity-adjusted life years (DALY), which considers fatal and 
non-fatal outcomes.43
Although ZIKV has a high rate of transmission, with 
an estimated 73% of the population infected in the 
outbreak in Micronesia9 and 66% in French Polynesia,44 
until 2015, ZIKV was considered a mild disease, without 
complications, hospitalisations or mortality. Now we 
know Zika can cause congenital ZIKV infection, GBS and 
other severe neurological complications. In late 2015, in 
French Polynesia, 42 patients were diagnosed with GBS 
during the ZIKV outbreak.45 Based on the 66% attack 
rate of ZIKV infection, the risk of GBS in the population 
was estimated to be 1 for each 4000 ZIKV infections.46 A 
case–control study in French Polynesia showed a 34-fold 
increase in risk of GBS in those with markers of ZIKV 
infection.46 If we apply the same attack rate and the risk 
of GBS to the Brazilian population, we can expect 32.390 
cases of Zika-related GBS in Brazil. Other neurological 
complications such as acute myelitis47 and meningoen-
cephalitis48 have been associated with Zika.
An increase in neonates with microcephaly was 
noticed initially in Brazil, and retrospectively in the 
French Polynesia. The number of notified suspected 
cases in Brazil reached more than 10.000 and almost 
3000 confirmed congenital syndrome associated with 
Zika.49 At the time of writing, microcephaly has been 
reported in the Americas, Pacific Islands and African 
countries and territories, where the ZIKV epidemic 
started later than in Brazil. Scientific evidence for the 
causal relationship between congenital transmission 
of ZIKV and microcephaly was produced fast and the 
link recognised.50 A preliminary report of follow-up 
of pregnant women with Zika conducted in Brazil 
showed a risk of 22% of microcephaly after symptom-
atic ZIKV infection in the first trimester, and started 
the long process of describing the whole spectrum of 
the congenital Zika syndrome, of which microcephaly 
appears to be only at the tip of the iceberg.21 51 There 
are numerous cohorts of pregnant women going on 
and we will be able to describe the spectrum of the 
syndrome and answer others’ important questions such 
as the risks of adverse outcomes among fetuses whose 
mothers were infected and factors associated with 
adverse fetal outcomes. So far, Zika is the only flavi-
virus to cause congenital infection in humans, and the 
response to this epidemic required addressing the state 
of sexual and reproductive rights.52
Chikungunya infection outbreaks can affect a large 
proportion of the population. Chikungunya can severely 
reduce quality of life due to postchikungunya rheuma-
tism that can destroy joints, impair daily life and require 
treatment with antirheumatic drugs; chikungunya can 
also worsen pre-existing chronic inflammatory rheuma-
tism. Among confirmed cases of chikungunya in France, 
15 months after the acute disease, 57% of the patients 
were still experiencing rheumatic manifestations.53 The 
chronic pain and rheumatism among patients after chiku-
ngunya infection might have impact on mental health of 
patients.54 It was estimated that according to the number 
of reported cases of chikungunya during 2014 in the 
Americas, 38 million patients will develop chronic inflam-
matory rheumatism.55
In La Reunion Island, a range of new clinical forms 
(respiratory and cardiovascular failure, meningoenceph-
alitis and other central nervous system problems, severe 
acute hepatitis, severe cutaneous effects and kidney 
failure) was identified; 57 patients were diagnosed with 
central nervous system disease, including 24 with enceph-
alitis.56 In Latin America, the burden of chikungunya 
was estimated in 25.45 DALYs per 100 000 of popula-
tion.57 The fatality rate of chikungunya was considered 
low, but there are indications that this was in part due to 
underascertainment. Although not causing congenital 
malformations, vertical transmission of chikungunya 
(predominantly during delivery) has been described as 
causing neurological complication in the neonate with 
cognitive development delays.58
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conclusIon
The emergence of ZIKV and CHIK and the re-emer-
gence of DENV in Brazil established a situation that 
was probably unprecedented: the circulation at high 
incidence of three arboviruses transmitted by the same 
mosquito, A. aegypti, in the same, mostly urban, space: 
DENV, CHIKV and ZIKV. The three arboviruses 
are causing epidemics in several cities in Brazil and 
the Americas, causing morbidity and high levels of 
unpredicted complications, increasing demand on 
health services, and other support services. This is 
not trivial because the situation is new, and because it 
exposed the limitation of the current available meas-
ures for control, which do not appear to be effective 
in preventing, or reducing sufficiently the circulation 
of these arboviruses, two of which (ZIKV and CHIKV) 
are new to the Americas, and therefore are meeting 
a totally susceptible population. As they disseminate 
through the Americas (and further) in cities infected 
by A. aegypti and/or A. albopictus, epidemics will follow.
There are many other arboviruses waiting in the 
wings, and the experience with DENV, CHIKV and ZIKV 
makes it clear that introductions of new pathogens are 
likely to happen, causing new explosive epidemics and 
increasing the burden caused by the cocirculation. 
Preparing for new and current epidemics requires 
measures that are specific to each virus, and measures 
that are common, mainly directed at controlling 
mosquito populations.
The current situation is complex, because there is 
no vaccine (except for dengue, recently licensed in 
Mexico, Philippines and Brazil), and no specific treat-
ment for the three arboviruses. Vector control is the 
only comprehensive solution and this remains a chal-
lenge because no measure achieved effective mosquito 
control yet, in the decades of dengue programme 
control worldwide. Until we develop better technolo-
gies to control mosquito populations, the globalised 
and urbanised world we live in will remain vulnerable 
to the threat of successive arbovirus epidemics.
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